HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 291/4/G545    most recent 00122.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Sarna, S. K. Search for Related Content PubMed PubMed Citation Articles by Sarna, S. K.

INVITED REVIEWS

Molecular, functional, and pharmacological targets for the development of gut promotility drugs

Enteric Neuromuscular Disorders and Visceral Pain Center, Division of Gastroenterology, Departments of Internal Medicine, Neuroscience, and Cell Biology, University of Texas Medical Branch at Galveston, Galveston, Texas

ABSTRACT

The science of gastrointestinal motility has made phenomenal advances during the last fifty years. Yet, there is a paucity of effective promotility drugs to treat functional bowel disorders that affect 10–29% of the U.S. population. A part of the reason for the lack of effective drugs is our limited understanding of the etiology of these diseases. In the absence of this information, mostly an ad hoc approach has been used to develop the currently available drugs, which are modestly effective or effective in only a subset of the patients with functional bowel disorders. This review discusses a grounds-up approach for development of the next generation of promotility drugs. The approach is based on our current understanding of 1) the different types of contractions that produce overall motility function of mixing and orderly net distal propulsion in major gut organs, 2) the regulatory mechanisms of these contractions, 3) which receptors and intracellular signaling molecules could be targeted to stimulate specific types of contractions to accelerate or retard transit, and 4) the strengths and limitations of animal models and experimental approaches that could screen potential promotility drugs for their efficacy in human gut propulsion in functional bowel disorders.

smooth muscle; slow waves; enteric neurons; excitation-contraction coupling; peristaltic reflex; irritable bowel syndrome; prokinetic agents; gastroparesis; functional bowel disorders

This article has been cited by other articles:

				G. Gourcerol, L. Wang, D. W. Adelson, M. Larauche, Y. Tache, and M. Million Cholinergic giant migrating contractions in conscious mouse colon assessed by using a novel noninvasive solid-state manometry method: modulation by stressors Am J Physiol Gastrointest Liver Physiol, May 1, 2009; 296(5): G992 - G1002. [Abstract] [Full Text] [PDF]

				X.-Z. Shi and S. K. Sarna Gene therapy of Cav1.2 channel with VIP and VIP receptor agonists and antagonists: a novel approach to designing promotility and antimotility agents Am J Physiol Gastrointest Liver Physiol, July 1, 2008; 295(1): G187 - G196. [Abstract] [Full Text] [PDF]

				S. K. Sarna Are interstitial cells of Cajal plurifunction cells in the gut? Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G372 - G390. [Abstract] [Full Text] [PDF]

				S. K. Sarna Enteric descending and afferent neural signaling stimulated by giant migrating contractions: essential contributing factors to visceral pain Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G572 - G581. [Abstract] [Full Text] [PDF]